mash and glp 1 Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD MASH: Network Meta-Analysis of Clinical Trials Beyond GLP-1: The Biological Case

In the FLOW clinical trial, semaglutide reduced the risk of some adverse outcomes for participants who had both type 2 diabetes and chronic kidney disease

For people who meet the criteria and are comfortable with a telehealth model, AltRx can be a practical entry point into GLP-1 treatment

SURPASS trials: type 2 diabetes data The SURPASS trial series examined tirzepatide versus semaglutide specifically in patients with type 2 diabetes

Continued innovation in long-acting injectable formulations further supports market expansion

We would also like to thank the clinical research teams at each study site who worked on the GLIDE trial

GLP-1 and GLP-1R In 1932, Jean La Barre purified the glucose-lowering element from gut extracts and named it INtestine seCRETtion Insulin (incretin) [[18], [19], [20]]